Bharat Book

Conference on 5th Annual Smoking Cessation

Event

27
JAN
BSG Conference Centre, London, UK
-   -

Conference on 5th Annual Smoking Cessation
To be held at 27th – 28th January 2011, BSG Conference Centre, London, UK

Key Speakers for Conference on 5th Annual Smoking Cessation

Raymond Hreiche, Regional Scientific Advisor, Pfizer
Senior Representative, GSK
Mike Kelly, Public Health Director, National Institute for Health and Clinical Excellence (NICE)
Raafat Fahim, President and CEO, Nabi Biopharmaceuticals
Scott Bryson, Lead Specialist in Pharmaceutical Public Health, NHS
Robert Walton, Professor of Primary Medical Care, Barts and The London School of Medicine and Dentistry
Dave Clark, Campaigns and Policy officer, Action on Smoking and Health (ASH)
Simon Gilbody, Professor of Psychological Medicine and Health Services, University of York

Conference on 5th Annual Smoking Cessation Introduction
27th – 28th January 2011, London, UK

Smoking remains one of the biggest health threats in the world, causing 5.4 million deaths worldwide and 100,000 deaths in the UK each year. With governments and health organisations constantly warning of dangers of smoking, there’s never been more pressure on smokers to quit. Figures suggest that around 50% of quit attempts involve the use of smoking cessation aids, usually in the form of nicotine replacement therapy (NRT), purchased over the counter. Most unaided attempts are often not very successful. There is a growing market for new, safe and more effective smoking cessation therapies. This will see the global smoking cessation products market increase with a CAGR of 5% during the period 2008-2024, with revenues increasing from $3504m in 2008, to $7347m by 2024. Growth will be most noted in the emerging economies of Brazil, Russia, China and India (BRIC). Having hosted four previous successful Smoking Cessation events, We are now preparing for its 5th Annual Smoking Cessation conference. This conference will feature key industry experts who will discuss the latest in anti-smoking therapies, examine the challenges in the smoking cessation market, and review current control policies and preventative measures.

Why you should attend this Conference on 5th Annual Smoking Cessation:
• Examine the current market potential for emerging anti-smoking products
• Hear the latest innovations in smoking cessation therapies
• Assess the health benefits of smoking cessation
• Understand the effects of smoking on the human body
• Identify novel therapeutic targets for smoking cessation products
• Review the latest in tobacco prevention and control policies
• Use this opportunity as a platform for future collaborations

Who should attend Conference on 5th Annual Smoking Cessation?
VPs, Directors, Heads and Managers of:
• Smoking Cessation
• Anti-smoking Products
• Tobacco Risk/Control
• Tobacco Research
• Clinical Trials
• Clinical Pharmacology
• Pharmacotherapy
• Drug Delivery
• Research & Development
• Scientific Affairs
• Primary Care
• Respiratory
• COPD
• Therapeutics
• Drug Addiction
• Health Improvement
• Epidemiology
• Consumer Insights
• Outcomes Research
• Product Development
• Pricing
• Marketing/Sales
• Public Affairs/Branding/Advertising
• Regulatory Affairs

Members of:
• Pharma, Biotech & Healthcare Organisations
• Government - Department of Health, NHS PCTs
• Non-profit Organisations/Associations
• Advertising/Public Relations Bodies
• Hospitals

Conference on 5th Annual Smoking Cessation Day 1
Thursday 27th January 2011

09:00 Registration and refreshments

09:30 Opening address from the chair

09:40 Smuggling and smoking: reducing the harm caused by the illicit trade
• What is illicit tobacco – extent and nature of the problem
• The price of smuggling - impact of illicit sales on tobacco control policies
• The impact of smuggling on health inequalities
• Tackling the illicit trade - establishing an international illicit trade protocol and other initiatives

Dave Clark
Campaigns and Policy officer, Action on Smoking and Health (ASH)

10:20 Varenicline medical update: a special look at smokers with co-morbidities
• New clinical data in CV and COPD smokers
• Varenicline in real-life clinical practice
• Varenicline safety update

Raymond Hreiche
Regional Scientific Advisor, Pfizer

11:00 Morning refreshments

11:20 NicVAX; A promising aid to smoking cessation and long term abstinence
• Introduction: mortality, morbidity and health care burden of smoking
• The unmet medical need; inadequacy of current smoking cessation therapies
• NicVAX “proof of concept” and progress towards the objective

Raafat Fahim
President and CEO, Nabi Biopharmaceuticals

12:00 Can we get anymore out of NRT?
• Success rates
• Current limitations
• Future directions

12:40 Networking lunch

13:40 Drugs for smoking cessation don’t work!!
• The high rate of patient relapse in smoking cessation would not be tolerated in other therapeutic categories
• How can the relapse rate to reduced?
• What are the implications for new product development?
• Will these initiatives work in developing markets?

Rick Stewart
Chairman & Chief Executive Officer Extab Corporation

14:20 WHO perspective
• Tobacco epidemic
• The impact of the interventions
• Possible future measurements

15:00 Afternoon Refreshments

15:20 Product information, tailored programmes, social support? What smokers want when they go online?
• What is the cyber landscape for smokers?
• Do they talk to each other, and what do they say?
• How do you influence their decisions and help them change their behaviour?

Trevor van Mierlo
CEO, Evolution Health Systems

16:00 The relationship between tobacco and illnesses
• Tobacco as a risk factor for the development of major illnesses
• The impact of smoking on pre-existing conditions
• The role smoking cessation in prevention

16:40 Closing remarks from the chair
16:50 Networking drinks
Take your discussions further and build new relationships in a relaxed and informal setting

Conference on 5th Annual Smoking Cessation Day 2
Friday 28th January 2011

09:00 Registration and refreshments

09:30 Opening address from the chair

09:40 Helping people with severe mental illness to quit smoking: what works?

• People with severe mental health problems such as schizophrenia are twice as likely to smoke as the rest of the population, and they die of average 20 years sooner – largely die to smoking-related illnesses
• More than half express an interest in cutting down or quitting, but do not readily engage with traditional NHS Stop Smoking Services
• Clear evidence now exits about ‘what works’ to help people with SMI to quit smoking, and NHS services might need to take account of the specific needs of this population to address this health inequality

Simon Gilbody
Professor of Psychological Medicine and Health Services, University of York

10:20 Genetic effects on smoking cessation and response to treatment
• Survey of research evidence to date
• Systematic overview and meta analysis of randomised trials
• Future directions for personalised treatment

Robert Walton
Professor of Primary Medical Care, Barts and The London School of Medicine and Dentistry

11:00 Morning refreshments

11:20 The HEAT is on: How community pharmacy contributes to national smoking cessation targets in Scotland
• Shifting the model of service provision from GPs to pharmacists
- a 5 year journey
• Outcome assessment - factors facilitating and inhibiting success
• Comparative effectiveness of smoking cessation therapies in the context of this service model
• Partnerships for success - the importance of joint working within and beyond the NHS
• The way forward - horizon scanning for future opportunities

Scott Bryson
Lead Specialist in Pharmaceutical Public Health, NHS

12:00 Presentation to be announced
Senior Representative, GSK

12:40 Networking lunch

13:40 NICE’s guidance on quitting smoking
• The role of cessation services
• Smoking and pregnancy
• Future directions

Mike Kelly
Public Health Director, National Institute for Health and Clinical Excellence (NICE)

14:20 Examining the growing market in smoking cessation
• The current market scenario and expansion
• The emphasis on controls and greater awareness
• Government/NGO initiatives in the developing world
• The approach and strategy

Ashok Narasimhan
Managing Director, Zenara
15:00 Afternoon refreshments
15:20 Market potential for new anti-smoking products
• Current trend
• Limited pool of effective anti-smoking products
• Identifying novel therapies

16:00 Smoking cessation in BRIC:
• Prevalence of smoking in these countries
• Tobacco control and legislation
• How can smoking cessation services and products currently used in the West, be extended to these parts of the world?

16:40 Chair’s closing remarks

16:50 End of Conference.

For more please visit
http://www.bharatbook.com/detail.asp?id=145725&rt=Conference-on-5th-Annual-Smoking-Cessation.html
OR Contact us at

Bharat Book Bureau
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com

Sign Up

Sign up for the event